Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial

Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study

(2011) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer

(2010) Kirsten Vang Nielsen et al.   BREAST CANCER RESEARCH AND TREATMENT

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Estrogen receptor α geneESR1amplification may predict endocrine therapy responsiveness in breast cancer patients

(2009) Saori Tomita et al.   CANCER SCIENCE

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute

Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Absence of ESR1 amplification in a series of breast cancers

(2008) José Adélaïde et al.   INTERNATIONAL JOURNAL OF CANCER

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

(2008) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY

ESR1 gene amplification in breast cancer: a common phenomenon?

(2008) Jorge S Reis-Filho et al.   NATURE GENETICS

Reply to “ESR1 gene amplification in breast cancer: a common phenomenon?”

(2008) Frederik Holst et al.   NATURE GENETICS

Conflicting evidence on the frequency of ESR1 amplification in breast cancer

(2008) Donna G Albertson   NATURE GENETICS

ESR1 gene amplification in breast cancer: a common phenomenon?

(2008) Lindsay A Brown et al.   NATURE GENETICS

ESR1 gene amplification in breast cancer: a common phenomenon?

(2008) Hugo M Horlings et al.   NATURE GENETICS

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

(2007) Birgitte B Rasmussen et al.   LANCET ONCOLOGY